Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President | May 07, 2022 | May 10, 2022 |
| CorMedix Inc.CRMD · Entity 5280 | Director · Chief Executive Officer | February 04, 2026 | February 07, 2026 |
| TALPHERA, INC.TLPH · Entity 7102 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 07, 2022 · Filed May 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 327,194 |
Ending reported balance
After 2022-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-07 · Exercise / conversion · Acquired 4,442 · Balance 328,756 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2022-05-07 · Tax withholding · Disposed 1,562 · Balance 327,194 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-07 · Exercise / conversion · Disposed 4,442 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
CorMedix Inc.
Report date February 04, 2026 · Filed February 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 774,749 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 77,156 · Balance 774,749 F1: Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person.
TALPHERA, INC.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,497 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 5,100 · Balance 11,497 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-06-21 | Direct | 30,700 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 30,700 · Balance 30,700 F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2022 Filed Mar 1, 2022 22:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,107 | $4.59 | $50,981.13 |
DisclosureSEC source: 0001209191-22-014150 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,896 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 29,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014150 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 23:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 1,500 | $4.10 | $6,150.00 |
DisclosureSEC source: 0001209191-21-067956 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,319 Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-031567 · doc4.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,442 Underlying: Class A Common Stock · 4,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 1,562 | $5.20 | $8,122.40 |
DisclosureSEC source: 0001209191-21-031567 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,819 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-031567 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:05 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,330 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-21-021303 · doc4.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,331 Underlying: Class A Common Stock · 36,330 shares Expires 2028-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on May 7, 2018 and the total award of 72,661 options vests in four equal installments on May 7, 2019, May 7, 2020, May 7, 2021 and May 7, 2022. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:05 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 36,330 | $6.82 | $247,865.06 |
DisclosureSEC source: 0001209191-21-021303 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,940 F1 · price: This transaction was executed in multiple trades at prices ranging from $6.82 to $6.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:05 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 36,330 | $2.75 | $99,907.50 |
DisclosureSEC source: 0001209191-21-021303 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:39 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016065 · doc4.xml · derivative · entry 6 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,222 Underlying: Class A Common Stock · 11,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock units represents a contingent right to receive on share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:39 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 3,906 | $5.18 | $20,233.08 |
DisclosureSEC source: 0001209191-21-016065 · doc4.xml · nonDerivative · entry 4 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,940 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:39 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 11,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-016065 · doc4.xml · nonDerivative · entry 3 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock units represents a contingent right to receive on share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 212,356 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017002 · doc4.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,356 Underlying: Class A Common Stock · 212,356 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F5 · derivative.exercise_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. F5 · derivative.expiration_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 106,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017002 · doc4.xml · derivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,178 Underlying: Class A Common Stock · 106,178 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:39 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 29,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016065 · doc4.xml · derivative · entry 5 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,051 Underlying: Class A Common Stock · 29,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock units represents a contingent right to receive on share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27,2020, the reporting person was granted 118,734 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27,2020, the reporting person was granted 118,734 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:39 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 10,972 | $5.39 | $59,139.08 |
DisclosureSEC source: 0001209191-21-016065 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,735 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:39 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 29,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-016065 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock units represents a contingent right to receive on share of the Issuer's Class A Common Stock. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012452 · doc4.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,883 Underlying: Class A Common Stock · 4,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 2,212 | $3.55 | $7,852.60 |
DisclosureSEC source: 0000899243-20-012452 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,024 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:11 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012452 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006807 · doc4.xml · derivative · entry 4 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Class A Common Stock · 11,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 6,162 | $3.85 | $23,723.70 |
DisclosureSEC source: 0000899243-20-006807 · doc4.xml · nonDerivative · entry 3 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,794 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 11,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-006807 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3 F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 40,000 | $3.62 | $144,800.00 |
DisclosureSEC source: 0000899243-20-006807 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,845 Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 237,468 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006637 · doc4.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,468 Underlying: Class A Common Stock · 237,468 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F5 · derivative.exercise_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. F5 · derivative.expiration_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 118,734 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006637 · doc4.xml · derivative · entry 1 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,734 Underlying: Class A Common Stock · 118,734 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on February 27, 2021. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on February 27, 2021. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 90,498 | Not disclosed Strike: $2.75 | Not disclosed |
DisclosureSEC source: 0001723128-19-000131 · wf-form4_157377043282006.xml · derivative · entry 4 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,498 Underlying: Class A Common Stock · 90,498 shares Expires 2029-03-01 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Disposition to issuerStock Option · Derivative | 90,498 | Not disclosed Strike: $13.50 | Not disclosed |
DisclosureSEC source: 0001723128-19-000131 · wf-form4_157377043282006.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 90,498 shares Expires 2029-03-01 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 72,661 | Not disclosed Strike: $2.75 | Not disclosed |
DisclosureSEC source: 0001723128-19-000131 · wf-form4_157377043282006.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,661 Underlying: Class A Common Stock · 72,661 shares Expires 2028-05-07 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. Read SEC document |
| November 13, 2019 Filed Nov 14, 2019 22:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Disposition to issuerStock Option · Derivative | 72,661 | Not disclosed Strike: $15.01 | Not disclosed |
DisclosureSEC source: 0001723128-19-000131 · wf-form4_157377043282006.xml · derivative · entry 1 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 72,661 shares Expires 2028-05-07 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019. Read SEC document |
| May 13, 2019 Filed May 13, 2019 21:27 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 15,000 | $9.88 | $148,200.00 |
DisclosureSEC source: 0001723128-19-000094 · wf-form4_155778282066089.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,590 F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.65 per share to $9.99 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:45 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000091 · wf-form4_155743829592270.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,325 Underlying: Class A Common Stock · 4,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:45 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 2,228 | $13.44 | $29,944.32 |
DisclosureSEC source: 0001723128-19-000091 · wf-form4_155743829592270.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,590 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:45 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000091 · wf-form4_155743829592270.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · SVP, Specialty Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.